Skip to main content
SpringerLink
Log in

Zusammenhänge zwischen Serum-Lipoproteinstoffwechsel und biliärem Lipidstoffwechsel

Interrelationships between serum lipoprotein metabolism and biliary lipid metabolism

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

This review concern with recent results regarding interrelationships between serum lipoprotein and bile acid metabolism. First, changes in bile acid metabolism in primary hyperlipoproteinaemia type II and type IV are described. In addition, influences of lipid-lowering drugs such as sitosterol, cholestyramine/colestipol, neomycin, nicotinic acid, clofibrate and thyroxin on serum lipoproteins and biliary lipid metabolism are discussed. Changes in lipoprotein metabolism in disorders of bilc acid metabolism and effects of primary and secundary bile acids on lipoprotein metabolism, hepatic cholesterol metabolism and intestinal cholesterol absorption are described. In the final discussion interrelationships between very low density lipoprotein — triglycerides and cholic acid metabolism as well as low density lipoprotein and chenodeoxycholic acid metabolism are stressed. The positive correlation between serum triglycerides and lithogenicity of bile is underlined and the possible significance of high density lipoprotein-cholesterol as precursor of biliary cholesterol is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

HLP:

Hyperlipoproteinämic

VLDL:

very-low-density Lipoproteine

LDL:

low-density Lipoproteine

HDL:

high-density Lipoproteine

CA:

Cholsäure

CDCA:

Chenodesoxycholsäure

UDCA:

Ursodesoxycholsäure

DCA:

Desoxycholsäure

LCAT:

Lecithin-Cholesterin-Acyltransferase

HMG-CoA-Reduktase:

Hydroxymethylglutaryl-Coenzym A-Reduktase

Literatur

Übersichten

  1. Ahlberg J (1979) Biliary lipid metabolism in hyperlipoproteinaemia and gallstone disease. Acta Chir Scand [Suppl] 492:1–32

    Google Scholar 

  2. Andersen E (1980) On the metabolism of cholesterol and bile acids in normo-and hyperlipidaemic subjects. Acta Med Scand [Suppl] 643:1–35

    Google Scholar 

  3. Brown MS, Kovanen PT, Goldstein JL (1981) Regulation of plasma cholesterol by lipoprotein receptors. Science 212:628–635

    Google Scholar 

  4. Danielsson H, Sjoevall J (1975) Bile acid metabolism. Ann Rev Biochem 44:233–253

    Google Scholar 

  5. Fisher MM, Goresky SM, Shaffer EA, Strasberg SM (eds) (1979) Gallstones. Plenum Press, New York London

    Google Scholar 

  6. Fredrickson DS, Goldstein JL, Brown MS (1978) The familial hyperlipoproteinemias. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The metabolic basis of inherited disease, Fourth Edition. McGraw-Hill, New York, pp 604–655

    Google Scholar 

  7. Goldman MA, Schwartz CC, Swell L, Vlahcevic ZR (1979) Bile acid metabolism in health and disease. In: Popper H, Schaffner F (eds) Progress in liver disease, Vol VI. Grune and Stratton, New York San Francisco London, pp 225–242

    Google Scholar 

  8. Grundy SM (1978) Cholesterol metabolism in man. West J Med 128:13–25

    Google Scholar 

  9. Havel RJ, Goldstein JL, Brown MS (1980) Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE (eds) Metabolic control and disease, 8th edition. WB Saunders, Philadelphia, pp 393–494

    Google Scholar 

  10. Hellstroem K, Einarsson K (1977) Bile acid metabolism in hyperlipoproteinaemia. Clin Gastroenterol 6:103–128

    Google Scholar 

  11. Hunninghake DB, Probstfield JL (1977) Drug treatment of hyperlipoproteinaemia. In: Rifkind BM, Levy RI (eds) Hyperlipidemia — diagnosis and therapy. Grune and Stratton, New York, pp 327–362

    Google Scholar 

  12. Lees AM, Lees RS (1979) Agents used to treat hyperlipidemia and atherosclerosis. In: Miller RR, Greenblatt DJ (eds) Handbook of drug therapy. Elsevier, New York Amsterdam pp 696–728

    Google Scholar 

  13. Leijd B (1980) Metabolism of plasma and biliary lipids in hyperlipoproteinaemia. Acta Med Scand [Suppl] 635

    Google Scholar 

  14. Levy RJ (1980) Drugs used in the treatment of hyperlipoproteinaemias. In: Goodman Gilman A, Goodman LS, Gilman A (eds) Goodman and Gilman's the pharmacological basis of therapeutics, Sixth edition. Macmillian Publishing Co, New York, pp 834–847

    Google Scholar 

  15. Smith LC, Pownall HJ, Gotto AM jr (1978) The plasma lipoproteins: structure and metabolism. Ann Rev Biochem 47:751–777

    Google Scholar 

  16. Paumgartner G, Stiehl A, Gerok W (eds) (1981) Bile acid and lipids. MTP Press Limited, Lancaster, England

    Google Scholar 

Einzelarbeiten

  1. Abrams JJ, Grundy SM, Ginsberg H (1981) Metabolism of plasma triglycerides in hypothyroidism and hyperthyroidism in man. J Lipid Res 22:307–322

    Google Scholar 

  2. Abrams JJ, Grundy SM (1981) Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res 22:323–338

    Google Scholar 

  3. Adler RD, Bennion LJ, Duane WC, Grundy SM (1975) Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. Gastroenterology 68:326–334

    Google Scholar 

  4. Ahlberg J, Angelin B, Einarsson K, Hellstroem K, Leijd B (1977) Influence of deoxycholic acid on biliary lipids in man. Clin Sci Mol Med 53:249–256

    Google Scholar 

  5. Ahlberg J, Angelin B, Einarsson K, Hellstroem K, Leijd B (1979) Prevalence of gallbladder disease in hyperlipoproteinaemia. Digest Dis Sci 24:459–464

    Google Scholar 

  6. Ahlberg J, Angelin B, Einarsson K, Hellstroem K, Leijd B (1980) Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology 79:90–94

    Google Scholar 

  7. Ahlberg J, Angelin B, Einarsson K (1981) Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of CA and CDCA treatment. J Lipid Res 22:410–422

    Google Scholar 

  8. Albers JJ, Grundy SM, Cleary PA, Small DM, Lachin J, Schoenfield LJ and the National Cooperative Gallstone Study Group (1982) National Cooperative Gallstone Study — The effect of cheodeoxycholic acid on lipoproteins and apolipoproteins. Gastroenterology 82:638–646

    Google Scholar 

  9. Andersen E, Hellstroem K (1980) Influence of fat-rich versus carbohydrate-rich diets on bile acid kinetics, biliary lipids, and net steroid belance in hyperlipidemic subjects. Metabolism 29:400–409

    Google Scholar 

  10. Anderson E, Hellstroem K (1979) The effect of cholesterol feeding on bile acid kinetics and biliary lipids in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 20:1020–1027

    Google Scholar 

  11. Angelin B, Einarsson K, Helstroem K, Kallner M (1976) Elimination of cholesterol in hyperlipoproteinaemia. Clin Sci Mol Med 51:393–397

    Google Scholar 

  12. Angelin B, Einarsson K, Hellstoem K, Leijd B (1978) Bile acid kinetics in relation to endogenous triglyceride metabolism in various types of hyperlipoproteinemia. J Lipid Res 19:1004–1016

    Google Scholar 

  13. Angelin B, Einarsson K, Hellstroem K, Leijd B (1978) Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinaemia. J Lipid Res 19:1017–1024

    Google Scholar 

  14. Angelin B, Einarsson K, Leijd B (1978) Effect of chenodeoxycholic acid on serum and bilary lipids in patients with hyperlipoproteinaemia. Clin Sci Mol Med 54:451–455

    Google Scholar 

  15. Angelin B, Einarsson K, Leijd B (1979) Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest 9:185–190

    Google Scholar 

  16. Angelin B, Einarsson K, Leijd B (1981) Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid. Eur J Clin Invest 11:185–189

    Google Scholar 

  17. Angelin B, Leijd B (1980) Effects of cholic acid on the metabolism of endogenous plasma triglyceride and on biliary lipid composition in hyperlipoproteinaemia. J Lipid Res 21:1–9

    Google Scholar 

  18. Bateson MC, Igbal J (1979) Chenodeoxycholic acid, post-prandial serum-triglycerides, and HDL-cholesterol Lancet I:930

    Google Scholar 

  19. Bateson MC, Igbal J (1979) Ursodeoxycholic acid and serum lipids. Lancet II:151

    Google Scholar 

  20. Bateson MC, Maclean D, Ross PE, Bouchier IAD (1978) Clofibrate therapy and gallstone induction. Digest Dis 23:623–628

    Google Scholar 

  21. Bateson MC, Ross PE, Murison J, Bouchier IAD (1978) Reversal of clofibrate-induced cholesterol oversaturation of bile with chenodeoxycholic acid. Br Med J I:1171–1173

    Google Scholar 

  22. Begemann F (1978) Influence of chenodeoxycholic acid on the kinetics of endogenous triglyceride metabolism in man. Eur J Clin Invest 8:283–288

    Google Scholar 

  23. Begemann F, Bandomer G, Herget HJ (1978) The influence of beta-sitosterol on biliary cholesterol saturation and bile acid kinetics in man. Scand J Gastroent 13:57–63

    Google Scholar 

  24. Bell GD, Lewis B, Petrie A, Dowling RH (1973) Serum lipids in cholclithiasis: effect of chenodeoxycholic acid therapy. Br Med J III:520–522

    Google Scholar 

  25. Bennion LJ, Grundy SM (1978) Risk factors for the development of cholelithiasis in man. N Engl J Med 299:1161–1167, 1221–1227

    Google Scholar 

  26. Bouchier IAD (1980) The medical treatment of gallstones. Ann Rev Med 31:59–77

    Google Scholar 

  27. Camarri E, Fici F, Marcolongo R (1978) Influence of chenodeoxycholic acid on serum triglycerides in patients with primary hypertriglyceridemia. Int J Clin Pharmacol 16:523–526

    Google Scholar 

  28. Camarri E, Marcolongo R, Zaccherotti L, Marini G (1978) The hypotriglyceridemic effect of chenodeoxycholic acid in type IV-hyperlipidemia. Biomedicine 29:193–198

    Google Scholar 

  29. Carlson LA (1978) Nicotinic acid and inhibition of fat mobilizing lipolysis: present status of effects on lipid metabolism. Adv Exp Med Biol 109:225–238

    Google Scholar 

  30. Carlson LA, Oro L (1973) Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 18:1–9

    Google Scholar 

  31. Carulli N, Ponz de Leon M, Loria P, Iori R, Rosi A, Romani M (1981) Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. Gastroenterology 81:539–546

    Google Scholar 

  32. Carulli N, Ponz de Leon M, Zironi F, Jori R, Loria P (1980) Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. Gastroenterology 79:637–641

    Google Scholar 

  33. Carulli N, Ponz de Leon M, Zironi F, Pinetti A, Smerieri A (1980) Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J Lipid Res 21:35–43

    Google Scholar 

  34. Chait A, Albers JJ, Bierman EA (1978) Regulation of low-density lipoprotein degration by triiodothyronine. Clin Res 26:303 (Abstr)

    Google Scholar 

  35. Clifton-Bligh P, Miller NE, Nestel PJ (1974) Increased plasma cholesterol esterifying activity during colestipol resin therapy. Metabolism 23:437–444

    Google Scholar 

  36. Connor WE, Witiak DT, Stone DB (1969) Cholesterol balance and fecal neutral steroid and bile acid excretion in normal men fed dietary fats of different fatty acid composition. J Clin Invest 48:1363–1375

    Google Scholar 

  37. Cooper J, Geizerova H, Oliver MF (1975) Clofibrate and gallstones. Lancet I:1083

    Google Scholar 

  38. Coronary Drug Project Research Group (1977) Gallbladder disease as a side effect of drugs influencing lipid metabolism. N Engl J Med 296:1185–1190

    Google Scholar 

  39. Day RC, Harry DS, McIntyre N (1979) Plasma lipoproteins and the liver. In: Wright R, Alberti KGMM, Karrian S, Millward-Sadler GM (eds) Liver and biliary disease, pathophysiology — diagnosis — management. Saunders Company, London, pp 63–82

    Google Scholar 

  40. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U (1969) A controlled clinical trial of a diet high in unsaturated fat — in preventing complications of atherosclerosis. Circulation 40 [Suppl 2]

  41. Dorr AE, Gundersen K, Schneider JC jr, Spencer TW, Martin WB (1978) Colestipol hydrochloride in hypercholesterolemic patients — effect on serum cholesterol and mortality. J Chron Dis 31:5–14

    Google Scholar 

  42. Dowling RH (1977) Chenodeoxyxholic acid therapy of gallstones. Clin Gastroenterol 6:141–163

    Google Scholar 

  43. Einarsson K, Grundy SM (1980) Effects of feeding cholic acid and chenodeoxycholic acid on cholesterol absorption and hepatic secretion of of biliary lipids in man. J Lip Res 21:23–34

    Google Scholar 

  44. Einarsson K, Hellstroem K (1972) The formation of bile acids in patients with three types of hyperlipoproteinaemia. Eur J Clin Invest 2:225–230

    Google Scholar 

  45. Einarsson K, Hellstroem K, Kallner M (1973) The effect of clofibrate on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV. Eur J Clin Invest 3:345–351

    Google Scholar 

  46. Einarsson K, Hellstroem K, Kallner M (1974) The effect of cholestyramine on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV. Eur J Clin Invest 4:405–410

    Google Scholar 

  47. Einarsson K, Hellstroem K, Kallner M (1974) Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinaemia. J Clin Invest 54:1301–1311

    Google Scholar 

  48. Einarsson K, Hellstroem K, Kallner M (1974) Effect of cholic acid feeding on bile acid kinetics and neutral fecal steroid excretion in hyperlipoproteinaemia (types II and IV). Metabolism 23:863–873

    Google Scholar 

  49. Einarsson K, Hellstroem K, Kallner M (1975) Gallbladder disease in hyperlipoproteinaemia. Lancet I:484–487

    Google Scholar 

  50. Einarsson K, Hellstroem K, Leijd B (1977) Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV. J Lab Clin Med 90:613–622

    Google Scholar 

  51. Faloon WW, Rubulis A, Rubert M (1969) Cholesterol lowering and fecal bile acid and neutral sterol alteration during oral neomycin. Clin Res 17:158

    Google Scholar 

  52. Fellin R, Baggio G, Briani G, Baiocchi MR, Manzato E, Baldo G, Crepaldi G (1987) Long-term trial with colestipol plus clofibrate in familial hypercholesterolemia. Atherosclerosis 29:241–249

    Google Scholar 

  53. Fellin R, Briani G, Ballestrieri P, Baggio G, Baiocchi MR, Crepaldi G Crepaldi G (1975) Long-term effects of colestipol (U-26,597 A) on plasma lipids in familial type II hyperbetalipoproteinaemia. Atherosclerosis 22:431–445

    Google Scholar 

  54. Fisher MM, Yousef IM (1973) Sex differences in the bile acid composition of human bile: studies in patients with and without gallstones. Can Med Assoc J 109:190–193

    Google Scholar 

  55. Fromm H, Carlson GL, Hofmann AF, Farivar S, Amin P (1980) Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids. Am J Physiol 239:G161-G166

    Google Scholar 

  56. Gallo-Torres HE, Miller ON, Hamilton JG (1979) Some effects of deoxycholate administration on the metabolism of cholesterol in man. Am J Clin Nutr 32:1363–1375

    Google Scholar 

  57. Gamble W, Wright LD (1961) Effect of nicotinic acid and related compounds on incorporation of mevalonic acid into cholesterol. Proc Soc Exp Biol Med 107:160–162

    Google Scholar 

  58. Gerolami A, Sarles H (1975) Beta-sitosterol and chenodeoxycholic acid in the treatment of cholesterol gallstones. Lancet II:721

    Google Scholar 

  59. Gey KF, Carlson LA (eds) Metabolic effects of nicotinic acid and its derivatives. Hans Huber Pub, Bern

  60. Glomset JA (1972) Plasma lecithin: cholesterol acyltransferase. In: Nelson GJ (editor) Blood lipids and lipoproteins. John Wiley & Sons, Inc, New York, pp 745–788

    Google Scholar 

  61. Goldberg AP, Appelbaum-Bowden DM, Bierman EL, et al (1979) Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301:1073–1076

    Google Scholar 

  62. Goldsmith GA, Hamilton JG, Miller NO (1960) Lowering of serum lipid concentrations. Mechanisms used by unsaturated fats, nicotinic acid and neomycin: excretion of sterols and bile acids. Arch Intern Med 105:512–517

    Google Scholar 

  63. Greten H, Lang PD, Schettler G (eds) (1979) Lipoproteine und Herzinfarkt. Neue Aspekte in Diagnostik und Therapie von Hyperlipidaemien. Verlag Gerhard Witzstrock, Baden-Baden Köln New York

    Google Scholar 

  64. Grundy SM (1979) Biliary lipids, gallstones and treatment of hyperlipoproteinemia. Eur J Clin Invest 9:179–180

    Google Scholar 

  65. Grundy SM, Ahrens EH jr, Salen G, Schreibmann PH, Nestel PJ (1972) Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13:531–551

    Google Scholar 

  66. Grundy SM, Metzger AL, Adler RD (1972) Mechanisms of lithogenic bile formation in american indian women with cholesterol gallstones. J Clin Invest 51:3026–3043

    Google Scholar 

  67. Grundy SM, Mok HYI (1976) Effects of low dose phytosterols on cholesterol adsoprtion in man. In: Greten H (editor) Lipoprotein metabolism. Springer, Berlin Heidelberg New York, pp 112–118

    Google Scholar 

  68. Grundy SM, Mok HYI, Zech L, Berman M (1981) Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22:24–36

    Google Scholar 

  69. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (1980) Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs 19:161–180

    Google Scholar 

  70. Heller FR, Desager JP, Harvengt C (1981) Plasma lipid concentrations and lecithin: cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 30:67–71

    Google Scholar 

  71. Hellstroem K, Lindstedt S (1964) Cholic-acid turnover and biliary bile acid composition in humans with abnormal thyroid function. J Lab Clin Med 63:666–679

    Google Scholar 

  72. Hoffman NE, Hofmann AF, Thistle JL (1974) Effect of bile acid feeding on cholesterol metabolism in gallstone patients. Mayo Clin Proc 49:236–23

    Google Scholar 

  73. Hofmann AF, Paumgartner G (eds) (1975) Chenodeoxycholic Acid Therapy of Gallstones — Progress Report 1975. Schattauer, Stuttgart

    Google Scholar 

  74. Kadziolka R, Nilsson S, Schersten T (1977) Prevalence of hyperlipoproteinemia in mean with gallstone disease. Scand J Gastroent 12:353–355

    Google Scholar 

  75. Kane JP, Mallory MJ, Tun P, Phillips NR, Freedman DD, Williams ML, Rowe JS, Havel RJ (1981) Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 304:251–258

    Google Scholar 

  76. Kallner M (1975) The effect of chenodeoxycholic acid feeding on bile acid kinetics and fecal neutral steroid excretion in patients with hyperlipoproteinaemia types II and IV. J Lab Clin Med 86:595–604

    Google Scholar 

  77. Kern F jr, Everson GT, DeMarc B, McKinley M, Showalter R, Erfling W, Braverman DZ, Szcepanik van Leeuwen P, Klein PD (1981) Biliary lipids, bile acids, and gallbladder function in the human female. J Clin Invest 68:1229–1242

    Google Scholar 

  78. Kissebah AH, Adams PW, Harrigan P, Wynn V (1974) The mechanism of action of clofibrate and tetranicotinylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia. Eur J Clin Invest 4:163–174

    Google Scholar 

  79. Klose G, Mordasini R, Middelhoff G, Augustin J, Greten H (1978) Medikamentöse Behandlung primärer Hyperlipoproteinämien. Klin Wochenschr 56:99–110

    Google Scholar 

  80. Kottke B (1969) Differences in bile acid excretion. Primary hypercholesteremia compared to combined hypercholesteremia and hypertriglyceridemia. Circulation 40:13–20

    Google Scholar 

  81. Kutz K, Schulze A (1981) Effect of ursodeoxycholic acid on bile supersaturated with cholesterol in patients pretreated with clofibrate. Z Gastroenterol 19:231–236

    Google Scholar 

  82. Lageder H (1980) Vergleichende Doppelblinduntersuchung von Bezafibrat und Clofibrat bei Patienten mit primaerer Hyperlipoproteinämie. Wien Klin Wochenschr 92:95–101

    Google Scholar 

  83. La Russo NF, Szczepanik PA, Hofmann AF (1977) Effect of deoxycholic acid ingestion on bile acid metabolism and biliary lipid secretion in normal subjects. Gastroenterology 72:132–140

    Google Scholar 

  84. Lees RS, Lees AM (1976) Effects of sitosterol therapy on plasma lipid and lipoprotein concentrations. In: Greten H (ed) Lipoprotein metabolism, Springer, Berlin Heidelberg New York, pp 119–124

    Google Scholar 

  85. Lees AM, Mok HYI, Lees RS, McCluskey MA, Grundy SM (1977) Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholestrolemia and studies of sterol balance. Atherosclerosis 28:325–338

    Google Scholar 

  86. Leiß O, Bosch T, von Bergmann K (1981) Effects of bile acid feeding on lipoprotein concentration, change in cholesterol synthesis and biliary lipid secretion in patients with radiolucent gallstones. In: Paumgartner G, Stiehl A, Gerok W (eds) Bile acids and lipids. MTP Press, Lancaster, pp 247–253

    Google Scholar 

  87. Leiß O, von Bergmann K (1982) Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentration in patients with radiolucent gallstones. Scand J Gastroenterol 17:587–592

    Google Scholar 

  88. Leveille GA, Powell RC, Sauberlich HE, et al (1963) Effect of orally and parenterally administered neomycin on plasma lipids of human subjects. Am J Clin Nutr 12:421–426

    Google Scholar 

  89. Levy RI, Frederickson DS, Stone NJ, et al. (1973) Cholestyramine in type II hyperlipoproteinemia — a double-blind trial. Ann Intern Med 79:51–58

    Google Scholar 

  90. Low-Beer TS, Pomare EW (1975) Can colonic bacterial metabolites predispose to cholesterol gall stones? Br Med J I:438–440

    Google Scholar 

  91. Mahley RW, Hui DY, Innerarity TL, Weisgraber K (1981) Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B, E and apo-E receptors. J Clin Invest 68:1197–1206

    Google Scholar 

  92. Maton PN, Ellis HJ, Higgins MJP, Dowling RH (1980) Hepatic HMG CoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids. Eur J Clin Invest 10:325–332

    Google Scholar 

  93. Maugdal DP, Bird R, Blackwood WS, Northfield TC (1978) Low-cholesterol diet: enhancement of effect of CDCA in patients with gall stones. Br Med J II:851–853

    Google Scholar 

  94. McIntyre N, Agorastos J, Owen JS, Harry DS (1979) The effect of cholestasis on plasma lipids and lipoproteins. In: Gentilini P, Popper H, Sherlock S, Teodori U (eds) Problems in intrahepatic cholestasis Karger, Basel, pp 116–120

    Google Scholar 

  95. Micheli H, Pometta D, Gustafson A (1979) Treatment of hyperlipoproteinemia type IIa with a new phenoxy-isobutiric acid derivative, procetofene. Int J Clin Pharmacol 17:503–506

    Google Scholar 

  96. Middelhoff G, Loeser B, Stiehl A, Greten H (1981) Bindung von Gallensäuren an HDL: Korrelation zu cholestatischen Lebererkrankungen. Verh Dtsch Ges Inn Med 87:917–920

    Google Scholar 

  97. Miettinen TA (1968) Effect of nicotinic acid on catabolism and synthesis of cholesterol in man. Clin Chim Acta 20:43–51

    Google Scholar 

  98. Miettinen TA (1968) Mechanism of serum cholesterol reduction by thyroid hormones in hypothyroidism. J Lab Clin Med 71:537–547

    Google Scholar 

  99. Miettinen TA (1969) Serum squalene and methyl sterols as indicators of cholesterol synthesis in vivo. Life Sci 8:713–721

    Google Scholar 

  100. Miettinen TA (1973) Effect of drugs on bile acid and cholesterol excretion. Excerpta Med Int Congr Ser 283:77–89

    Google Scholar 

  101. Miettinen TA (1979) Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects. J Clin Invest 64:1485–1493

    Google Scholar 

  102. Miettinen TA (1982) Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res 23:466–473

    Google Scholar 

  103. Miettinen TA, Pelkonen R, Nikkilae EA, Heinonen O (1967) Low excretion of fecal bile acids in a family with hypercholesterolemia. Acta Med Scand. 182:645–650

    Google Scholar 

  104. Miller JP (1976) Lecithin: cholesterol acyltransferase activity and cholestyramine resin therapy in man. Eur J Clin Invest 6:477–479

    Google Scholar 

  105. Miller NE, Clifton-Bligh P, Nestel P, Whyte HM (1973) Controlled clinical trial of a new bile acid sequestering resin, colestipol, in the treatment of hypercholesterolemia. Med J Aust 1:1223–1227

    Google Scholar 

  106. Miller NE, Nestel PJ (1974) Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet II:929–931

    Google Scholar 

  107. Mishkel M, Stein EA (1977) Primary type IV-hyperlipoproteinemia. In: Rifkind BM, Levy RI (eds) Hyperlipidemia — Diagnosis and therapy. Grune and Stratton New York, pp 177–203

    Google Scholar 

  108. Mitropoulos KA, Myant NB, Gibbon GF, Balasubramaniam S, Reeves BEA (1974) Cholesterol precursor pools for the synthesis of cholic and chenodeoxycholic acids in rats. J Biol Chem 249:6052–6056

    Google Scholar 

  109. Mok HYI, Grundy SM (1980) Cholesterol and bile acid absorption during bile acid therapy in obese subjects undergoing weight reduction. Gastroenterology 78:62–67

    Google Scholar 

  110. Mordasini R, Grandjean EM, Nobile PC, Paumgartner G, Riva G (1979) Procetofen — eine Alternative in der Behandlung der Hypercholesterinämie? Schweiz Med Wochenschr 109:1140–1143

    Google Scholar 

  111. Mordasini R, Riesen W, Oster P, Riva G (1982) Verhalten der High-density-Lipoproteine (HDL) unter medikamentöser lipidsenkender Behandlung. Schweiz Med Wochenschr 112:95–97

    Google Scholar 

  112. Motulsky G (1976) Current concepts in genetics: the genetic hyperlipidemias. N Engl J Med 294:823–827

    Google Scholar 

  113. Nikkilae EA, Kekki M (1972) Plasma endogenous triglyceride traansport in hypertriglyceriademia and effect of a hypolipidaemic drug (SU-13437). Eur J Clin Invest 2:231–238

    Google Scholar 

  114. Nikkila EA, Kekki M (1972) Plasma triglyceride metabolism in thyroid desease. J Clin Invest 51:2103–2114

    Google Scholar 

  115. Nestel PJ, Hunter JD (1974) Differences in bile acid excretion in subjects with hypercholesterolaemia, hypertriglyceriademia and overweight. Austr N Zealand J Med 4:491–496

    Google Scholar 

  116. Nestel PJ, Kudchodkar B (1975) Plasma squalene as an index of cholesterol synthesis. Clin Sci Mol Med 49:621–624

    Google Scholar 

  117. Olsson AG, Dairou F (1978) Acute effects of cholestyramine on serum lipoprotein concentrations in type II hyperlipoproteinaemia. Atherosclerosis 29:53–61

    Google Scholar 

  118. Olsson AG, Lang PD (1978) Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 31:421–428

    Google Scholar 

  119. Olson AG, Lang PD (1978) One-year study of the effect of bezafibrate on serum lioporotein concentrations in hyperlipoproteinaemia. atherosclerosis 31:429–433

    Google Scholar 

  120. Oster P, Schlierf G, Heuck C, Greten H, Gundert-Remy U, Haase W, Klose G, Nothelfer A, Raetzer H, Schellenberg B (1976) Sitosterol in type II hyperliporoteinemia. In: Greten H (editor) Lipoprotein metabolism. Springer, Berlin Heidelberg New York, pp 125–130

    Google Scholar 

  121. Palmer RH (1978) Prevalence of gallstones in hyperlipidemia and incidence during treatment with clofibrate and/or cholestyramine. Trans Assoc Am Physicians 91:424–432

    Google Scholar 

  122. Pearlman BJ, Marks JW, Bonorris GG, Schoenfield LJ (1979) Gallstone dissolution — a progress report. Clin Gastroenterol 8:123–140

    Google Scholar 

  123. Pederson L, Arnfred T, Thaysen HE (1974) Cholesterol kinetics in patients with cholesterol gallstones before and during chenodeoxycholic acid treatment. Scand J Gastroent 9:787–792

    Google Scholar 

  124. Pertsemlidis D, Panveliwalla D, Ahrens EH jr (1974) Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 66:565–573

    Google Scholar 

  125. Pollak OJ, Kritchevsky D (1981) Sitosterol. Monographs on atherosclerosis, Vol 10. Karger, Basel München Paris London New York Sidney

    Google Scholar 

  126. Pomare EW, Heaton KW (1973) Bile salt metabolism in patients with gallstones in functioning gallbladders. Gut 14:885–890

    Google Scholar 

  127. Ponz de Leon M, Carulli N, Loria P (1979) The effect of chendoeoxycholic acid (CDCA) on cholesterol absorption. Gastroenterology 77:223–230

    Google Scholar 

  128. Ponz de Leon M, Carulli N, Loria P, Iori R, Zironi F (1980) Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology 78:214–219

    Google Scholar 

  129. Powell RC, Nunes WT, Harting RS, et al (1962) The influences of nonabsorbable antibiotics on serum lipids and the excretion of neutral sterols and bile acids. Am J Clin Nutr 11:156–168

    Google Scholar 

  130. Report from Committee of Principal Investigators (1978) A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 40:1069–1118

    Google Scholar 

  131. Roessner S, Oreo L (1978) Effects on serum lipoproteins of procetofene in hyperlipoproteinemia: dose-response studies and comparison with clofibrate. In: Carlson LA (editor) International Conference on Atherosclerosis. Raven Press, New York, pp 135–140

    Google Scholar 

  132. Sabesin SM, Bertram PD, Freeman MR (1980) Lipoprotein metabolism in liver disease. Adv Inter Med 25:117–146

    Google Scholar 

  133. Sabesin SM, Ragland JB, Freeman MR (1979) Lipoprotein disturbances in liver disease. In: Popper H, Schaffner F (eds) Progress in liver disease, Vol VI. Grune and Straton, New York San Francisco London, pp 243–262

    Google Scholar 

  134. Sama C, LaRusso NF (1982) Effect of deoxycholic, chenodeoxycholic, and cholic acids on intestinal absorption of cholesterol in humans. Mayo Clinic Proc 57:44–50

    Google Scholar 

  135. Samuel P, Holtzman CM, Goldstein BS (1967) Long term reduction of serum cholesterol levels of patients with atherosclerosis by small doses of neomycin. Circulation 35:938–945

    Google Scholar 

  136. Samuel P, Steiner A (1959) Effect of neomycin on serum cholesterol level of man. Proc Soc Exp Biol Med 100:193–195

    Google Scholar 

  137. Sandhofer F, Sailer S, Braunsteiner H (1966) Plasmalipide bei Störungen der Schilddrüsenfunktion. Klin Wochenschr 44:433–436

    Google Scholar 

  138. Schlierf G, Chwat M, Feuerborn E, Wülfinghof E, Heuck CC, Kohlmeier M, Oster P, Stiehl A (1980) Biliary and plasma lipids and lipid-lowering chemotherapy — studies with clofibrate, fenofibrate and etofibrate in healthy volunteers. Atherosclerosis 36:323–329

    Google Scholar 

  139. Schlierf G, Fischer H, Roche A, Stiehl A, Oster P, Schellenberg B, Vollmar J (1980) Gallenlipide unter Bezafibrat. Muench Med Wochenschr 122:165–168

    Google Scholar 

  140. Schlierf G, Oster P, Heuck CC, Raetzer H, Schellenberg B (1978) Sitosterol in juvenile type II hyperlipoproteincmia. Atherosclerosis 30:245–248

    Google Scholar 

  141. Schwartz CC, Halloran LG, Vlahcevic ZR, Gregory DH, Swell L (1978) Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 200:62–64

    Google Scholar 

  142. Schwartz CC, Bermann M, Vlahcevic ZR, Halloran LG, Gregory DH (1978) Multicompartmental analysis of cholesterol metabolism in man: characterization of the hepatic bile acid and biliary cholesterol precursor sites. J Clin Invest 61:408–423

    Google Scholar 

  143. Sedaghat A, Samuel P, Crouse JR, Ahrens EH jr (1975) Effects of neomycin on absorption, synthesis, and/or flux of cholesterol in man. J Clin Invest 55:12–21

    Google Scholar 

  144. Seidel D (1977) Studien zur Charakterisierung und zum Stoffwechsel des Lipoprotein-X (Lp-X), des abnormen Lipoproteins der Cholestase. Klin Wochenschr 55:611–623

    Google Scholar 

  145. Shepherd J, Packard CJ, Bicker S, Veitch Lawrie TD, Morgan HG (1980) Cholestyramine promotes receptormediated low-density-lipoprotein catabolism. N Engl J Med 302:1219–1222

    Google Scholar 

  146. Shepherd J, Packard CJ, Morgan HG, Third JLHC, Steward JM, Lawrie TDV (1979) The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 33:433–444

    Google Scholar 

  147. Small DM (1977) Bile salts of the blood. High density lipoprotein systems and cholesterol removal. In: Bianchi L, Gerok W, Sickinger K (eds) Liver and bile. MTP Press Ltd, Lancaster, pp 89–100

    Google Scholar 

  148. Small DM, Atkinson D, Redgrave T, Shipley GG, Tall AR (1979) A biophysical approach to cholesterol transport from tissues to bile In: Fisher MM, Goresky CA, Shaffer EA, Strasberg SM (eds) Gallstones. Plenum Press New York Long, pp 113–129

    Google Scholar 

  149. Sniderman A, Thomas D, Marpole D, Teng B (1978) Low density lipoprotein. A metabolic pathway for return of cholesterol to the splanchnic bed. J Clin Invest 61:867–87

    Google Scholar 

  150. Stewart JM, Packard CJ, Boag DE, Lorimer AR, Shepherd J (1981) The effects of bezafibrate on low density lipoprotein (LDL) metabolism in type II hyperlipoproteinaemia. In: Lipoproteins and Coronary Ahterosclerosis, Lugano, October 1–3. Abstract Book, p 42

  151. Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet II:1005–1007

    Google Scholar 

  152. Stone NJ (1977) Primary type II-hyperlipoproteinemia. In: Rifkind BM, Levy RI (eds) Hyperlipidemia — diagnosis and therapy. Grune and Stratton, New York, pp 113–136

    Google Scholar 

  153. Sturdevant RAL, Pearce ML, Dayton S (1973) Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med 288:24–27

    Google Scholar 

  154. Tangedahl TN, Thistle JL, Hofmann AF, Kottke BA (1979) Effect of beta-sitosterol alone or in combination with chenic acid on cholesterol saturation of bile and cholesterol absorption in gallstone patients. Gastroenterology 76:1341–1346

    Google Scholar 

  155. Tangedahl TN, Hofmann AF, Kottke BA (1979) Biliary lipid secretion in hypercholesterolemia. J Lipid Res 20:125–133

    Google Scholar 

  156. Taylor KG, Holdsworth G, Galton DJ (1977) Clofibrate increases lipoprotein-lipase activity in adipose tissue of hypertriglyceridaemic patients. Lancet II:1106–1107

    Google Scholar 

  157. The Coronary Durg Project Research Group (1972) The coronary drug project: Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220:996–1008

    Google Scholar 

  158. The Coronary Drug Project Research Group (1975) Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 231:360–381

    Google Scholar 

  159. Thistle JL, Ott BJ, Ellefson RD (1978) Serum lipoprotein cholesterol changes during bile acid ingestion for gallstone dissolution. Gastroenterology 75:990 (Abstr)

    Google Scholar 

  160. Thistle JL, Turcott J, Ott BY, Carlson GL, LaRusso NF, Hofmann AF (1978) Ursodeoxycholic acid unsaturates bile at a lower dose than chenodeoxycholic acid. Gastroenterology 74:1103–1109

    Google Scholar 

  161. Thompson GR (1981) Plasma exchange for hypercholesterolaemia. Lancet 1:1246–1248

    Google Scholar 

  162. Thompson GR, Barrowman J, Gutierrez L, Dowling RH (1971) Action of neomycin on the intraluminal phase of lipid absorption. J Clin Invest 50:319–323

    Google Scholar 

  163. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael HJ et al (1980) Assessment of long term plasma exchange for familial hypercholesterolacmia. Br Heart J 43:668–680

    Google Scholar 

  164. Thornton JR, Heaton KW, Macfarlane DG (1981) A relation between high-density-lipoprotein cholesterol and bile cholesterol saturation. Br Med J 283:1352–1354

    Google Scholar 

  165. Utermann G (1978) Genetik familiärer Hyperlipoproteinämien. Internist 19:465–469

    Google Scholar 

  166. Van den Bosch JF, Claes PJ (1967) Correlation between the bile salt-precipitating capacity of derivatives of basic antibiotics and their plasma cholesterol lowering effect in vivo. Prog Biochem Pharmacol 2:97–104

    Google Scholar 

  167. Van der Linden W, Bergman F (1977) An analysis of data on human hepatic bile. Relationship between main bile components, serum cholesterol and serum triglycerides. Scand J Clin Lab Invest 37:741–747

    Google Scholar 

  168. Von Bergmann K, Bosch T, Leiß O (1981) Effect of different bile acid feeding on change of cholesterol synthesis in man. Hepatology 1:67C

    Google Scholar 

  169. Von Bergmann K, Gutsfeld M, Schulze-Hagen K, von Unruh G (1979) Effects of ursodeoxycholic acid on biliary lipid secretion in patients with radiolucent gallstones. In: Paumgartner G, Stiehl A, Gerok W (eds) Biological effects of bile acids. MTP Press Ltd, Lancaster, pp 61–66

    Google Scholar 

  170. Von Bergmann K, Lciß O (1982) Effect of bezafibrate and fenofibrate on cholesterol synthesis in hyperlipidemic patients. International Symposium, Dijon, March 13–14

  171. Von Bergmann K, Leiß O, Kutz K (1981) Effects of lipid lowering substances on biliary lipid metabolism in hyperlipidaemic patients. In: Lipoproteins and Coronary Atherosclerosis, Lugano, October 1–3. Abstract Book, p 190

  172. Von Bergmann K, Leiß O (1982) Effects of different bile acids on cholesterol absorption in man. VII International Bile Acid Meeting, Basel, October 12–14

  173. Von Bergmann K, Strottkoeter H, Leiß O (1981) Decreased cholesterol absorption during ursodeoxycholic acid administration. Hepatology 1:67D

    Google Scholar 

  174. Wallentin L (1978) Lecithin: cholesterol acyl transfer rate and high density lipoproteins in plasma during dietary and cholestyramine treatment of type II A hyperlipoproteinaemia. Eur J Clin Invest 8:383–389

    Google Scholar 

  175. Walton KW, Scott PJ, Dykes PW, Davids JWL (1965) The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-J-lowdensity lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci 29:217–238

    Google Scholar 

  176. Wechsler JG, Hutt V, Kloer H-U, Bode G, Ditschuneit H (1982) Wirkung von Bezafibrat bei primären Hyperlipidämien. Klin Wochenschr 60:97–105

    Google Scholar 

  177. Weisweiler P, Neureuther G, Schwandt P (1979) The effect of cholestyramine on lipoprotein lipids in patients with primary type II A hyperlipoproteinemia. Atherosclerosis 33, 295–300

    Google Scholar 

  178. Weisweiler P, Schwandt P (1977) Lipoproteinveränderungen unter Clofibrat bei Typ IV-Hyperlipoproteinämien. Klin Wochenschr 55:791–794

    Google Scholar 

  179. White LW (1971) Regulation of hepatic cholesterol biosynthesis by clofibrate administration. J Pharmacol Exp Ther 178:361–370

    Google Scholar 

  180. Williams G, Murphy GM, Dowling RH (1979) Effect of ursodeoxycholic acid (UDCA) on serum total and VLDL triglycerides in gallstone patients. Cli Sci 58:15

    Google Scholar 

  181. Witztum JL, Schonfeld G, Weidman SW (1976) The effects of colestipol on the metabolism of very-low-density lipoproteins in man. J Lab Clin Med 88:1008–1018

    Google Scholar 

  182. Wollenweber J, Stiehl A (1972) Größe der Pools und Turnover der primären Gallensäuren bei Hyperlipoproteinämien: Unterschiedliche Befunde bei Typ II- und Typ IV-Hyperlipoproteinämie. Klin Wochenschr 50:33–38

    Google Scholar 

  183. Wood PD, Shioda R, Estrich EL, et al. (1972) Effect of cholestyraminc on composition of duodenal bile in obese human subjects. Metabolism 21:107–116

    Google Scholar 

  184. Yeshurun D, Gotto AM (1976) Drug treatment of hyperlipidemia. Am J Med 60:379–396

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik Bonn-Venusberg, Germany

    Ottmar Leiß & Klaus von Bergmann

Authors
  1. Ottmar Leiß
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus von Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leiß, O., von Bergmann, K. Zusammenhänge zwischen Serum-Lipoproteinstoffwechsel und biliärem Lipidstoffwechsel. Klin Wochenschr 61, 579–592 (1983). https://doi.org/10.1007/BF01487336

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01487336

Key words

Search

Navigation